newsfilter
← Latest News
Business Wire·

Alnylam Collaborator Regeneron Secures FDA Approval of Livsayis™ (cemdisiran), the Seventh FDA-Approved Therapeutic from Alnylam's RNAi Platform in Less Than Nine Years

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration (FDA) has approved ...

Keywords
Biotechnology,Clinical Trials,FDA,Health,Pharmaceutical